HO-1 promotes aggressiveness and therapy resistance, resulting in a higher risk of cancer development and therapeutic failure because HO-1 accelerates the production of tumor neovasculature and confers a selective advantage in overcoming increased oxidative stress during carcinogenesis and therapy to tumor cells 178. The gene discussed is HMOX1; the disease is neoplasm.